Medetomidine hydrochloride

Research use only, not for human use.

A potent, highly selective α2-adrenoceptor agonist with Ki of 1.08 nM; used as both a surgical anesthetic and analgesic.

A potent, highly selective α2-adrenoceptor agonist with Ki of 1.08 nM; used as both a surgical anesthetic and analgesic.(In Vitro):Medetomidine (0-1 μM, 1 h) hydrochloride inhibits aldosterone release from the adrenocortical cell suspension.Medetomidine (10 nM) hydrochloride activates a kicking response in Cyprids.Medetomidine (1 μM) hydrochloride increases cellular cAMP production by activating β-like receptors in CHO cells.(In Vivo):Medetomidine (200 μg/kg, p.o. or i.m.) hydrochloride induces a sedation in cats.Medetomidine (20 μg/kg, i.v.) hydrochloride shows sedative and analgesic effects in dogs.Medetomidine (0.05-0.3 mg/kg, s.c.) hydrochloride protects against Diazinon-induced toxicosis in mice.

Medetomidine (0-1 μM, 1 h) hydrochloride inhibits aldosterone release from the adrenocortical cell suspension.Medetomidine (10 nM) hydrochloride activates a kicking response in Cyprids.Medetomidine (1 μM) hydrochloride increases cellular cAMP production by activating β-like receptors in CHO cells.

Medetomidine (200 μg/kg, p.o. or i.m.) hydrochloride induces a sedation in cats.Medetomidine (20 μg/kg, i.v.) hydrochloride shows sedative and analgesic effects in dogs.Medetomidine (0.05-0.3 mg/kg, s.c.) hydrochloride protects against Diazinon-induced toxicosis in mice. Animal Model:Diazinon (75 mg/kg, orally)-induced toxicosis in miceDosage:0.05, 0.1 and 0.3 mg/kgAdministration:Subcutaneous injection (s.c.), 15 min before Diazinon.Result:Protected the mice from the toxicity induced by Diazinon.Decreased the occurrence of Straub tail, excessive salivation and tremor. Increased the latencies to onset of tremor and death when compared with control.Animal Model:DogsDosage:20 μg/kg Administration:Intravenous injection (i.v.)Result:Showed sedative and analgesic effects.Increased in SAP, MAP, DAP, MPAP, PCWP, CVP, SVR, PVR, core body temperature.

MPV-785

Angiogenesis

Adrenergic Receptor

α2-adrenoceptor

Neurological Disease

——

86347-15-1

236.7405

C13H17ClN2

>98% (HPLC)

10 mM in DMSO

CC1=C(C(=CC=C1)C(C)C2=CN=CN2)C.Cl

1H-Imidazole, 5-[1-(2,3-dimethylphenyl)ethyl]-, hydrochloride (1:1)

(-20℃)

With Ice Pack

≥ 2 years